
|Articles|March 4, 2014
- Vol 31 No 3
- Volume 31
- Issue 3
Data Point
Author(s)Richard M. Berlin, MD
Three years deep in despair, he’s swallowed every pill I prescribed...
Advertisement
While reviewing the results of a drug study for treatment-resistant depression
Three years deep in despair, he’s swallowed
every pill I prescribed. Refusing ECT,
his family and I convinced him to give
research medication one last shot.
Unblinded data arrived today and glows
on my computer screen, each depressed
patient’s response graphed with a dot,
the experimental molecule clearly beating
placebo, my patient’s outlier point six feet under
the rising line of success, a speck of coal
on a snow-covered field, my mind expanding
the insignificant dot to a skull’s eye socket
staring me down like a Beretta’s bullet hole.
Articles in this issue
over 12 years ago
The New CPT Codes: Ethical Challenges in a New Billing Era?over 12 years ago
End-of-Life Decisions: Who Decides and the Role of the Psychiatristover 12 years ago
Revive Flurothyl Inhalation Therapyover 12 years ago
Prescribing Psychotropics for Women of Childbearing Potentialover 12 years ago
Introduction: The Brave New World of Psychiatric Ethicsover 12 years ago
Ethics and Virtues in Clinical PsychiatryAdvertisement
Related to this article

Cingulate shares plans to resubmit its ADHD candidate CTx-1301 to the FDA, following a CRL tied to CMC information requests

The American Society of Addiction Medicine has released the first clinical guide and national resource for managing the intoxication and withdrawal of medetomidine.

Digital memory tests flag subtle preclinical Alzheimer changes, especially with neocortical tau; scalable tools may boost future trial screening.

How ED physicians and psychiatrists team up to cut mental health boarding, reduce unnecessary tests, and deliver faster, safer ED crisis care.

In the second positive phase 3 trial of lumateperone (Caplyta) for bipolar mania, participants saw improved manic symptoms vs placebo as early as day 3.

Lipocine has dosed the first participant in BLOOM, their phase 3 study evaluating LPCN 1154 (oral brexanolone) for postpartum depression.

Reach Out and Read serves 4.8 million children, but 23% of parents at 3 centers reported clinician modeling, tied to the greatest home literacy gains.
Advertisement
Advertisement
Trending on Psychiatric Times
1
NDA Submission Complete: COMP360 Psilocybin for Treatment-Resistant Depression
2
Lumateperone Shows Significant and Rapid Improvement in Bipolar Mania
3
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
4
Updates on CTx-1301, NDA Resubmission After FDA Complete Response Letter
5

